FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/Investigating Tirzepatide’s Role in Post-Bariatric Surgery Patients: A New Clinical Trial
返回研究图书馆

Investigating Tirzepatide’s Role in Post-Bariatric Surgery Patients: A New Clinical Trial

May 25, 2026
Share
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文是基于最近发布的新闻或临床试验公告的人工智能辅助摘要。旨在为肽类研究社区提供快速、易懂的概览。欲获得完整准确性,请参阅下方提供的原始来源。

Investigating Tirzepatide’s Role in Post-Bariatric Surgery Patients: A New Clinical Trial

The Vanderbilt University Medical Center has initiated a new pilot clinical trial to assess the effectiveness and safety of Tirzepatide, a GLP-1 receptor agonist, for patients who have undergone Roux-en-Y gastric bypass surgery but continue to struggle with severe obesity. This groundbreaking research aims to provide evidence that could revolutionize post-surgical weight management strategies.

Background

Severe obesity remains a significant health concern even after bariatric surgery, with many patients struggling to achieve and maintain their surgical goals. The GLP-1 receptor agonists have shown promising results in managing diabetes and obesity but their use in the context of post-bariatric surgery has been less explored. Vanderbilt University Medical Center's recent clinical trial seeks to bridge this gap by focusing on the potential benefits of Tirzepatide, a newer and more potent form of GLP-1 receptor agonists.

Tirzepatide combines the effects of GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) to enhance glucose control and promote weight loss. The trial aims to determine whether this dual mechanism can effectively address persistent obesity in patients who have undergone Roux-en-Y gastric bypass surgery but still maintain a BMI greater than 30 twelve months post-operation.

Key Details

The GRABS (GLP-1 Receptor Agonists Post-Bariatric Surgery) pilot trial is currently enrolling participants and will be conducted over multiple phases, including Phase II and III. The study compares the outcomes of patients treated with Tirzepatide against those receiving standard care post-surgery. By analyzing weight loss, changes in body composition, and adverse effects, researchers hope to provide crucial insights into the long-term management of obesity.

This trial is particularly significant as it aims to fill a critical gap in current treatment options for obese individuals who have not achieved their desired outcomes after bariatric surgery. The FDA's approval of GLP-1 receptor agonists has already made them popular among clinicians and patients alike, but their efficacy beyond initial weight loss remains under investigation.

Key Takeaways

  • Tirzepatide Shows Promise: Early studies suggest that Tirzepatide may offer a more robust solution for persistent obesity compared to traditional GLP-1 receptor agonists.
  • Post-Surgery Management: This trial focuses on patients who continue to struggle with weight despite successful bariatric surgery, offering hope for those who have not seen long-term benefits from their operations.
  • Safety Profile: The study aims to gather data on the frequency and nature of side effects associated with Tirzepatide use in this specific patient population, ensuring a comprehensive understanding of its safety.
  • Clinical Impact: If successful, the GRABS trial could pave the way for wider acceptance of GLP-1 receptor agonists as part of long-term weight management strategies post-surgery.

What This Means

For the peptide community, the GRABS pilot trial represents an important step towards understanding how advanced peptides like Tirzepatide can be integrated into clinical practice to address complex health issues. The results could influence future research and regulatory decisions, potentially expanding the use of GLP-1 receptor agonists beyond their current applications.

This study underscores the ongoing importance of peptide therapy in modern medicine and highlights the need for continued investigation into novel treatments for obesity and related conditions. As more clinical trials like GRABS produce valuable data, the landscape of peptide research will continue to evolve, offering new hope to patients and healthcare providers alike.

---

Source: ClinicalTrials.gov — Published 2026-05-19

This article is for informational purposes only and does not constitute medical advice.

编辑注释

此分析使用人工智能工具生成,并由Peptide Contacts编辑团队审核。尽管我们力求准确,但人工智能生成的内容可能包含错误或遗漏。鼓励读者查阅 原始来源 以获取完整细节、方法和数据。

Peptide Contacts提供研究摘要仅供信息参考之用。此内容不构成医疗建议。在做出任何健康决策前,请咨询合格的医疗服务提供者。

Comments

Sign in to join the discussion

本文由人工智能生成,可能存在不准确之处。仅供信息参考之用,并不构成医疗建议。请务必通过原始来源核实信息并在做出任何健康决策前咨询合格的医疗服务提供者。